

Freedom of Information Request	FOI 23-440	11 October 2023
--------------------------------	------------	-----------------

Your request

You requested the following:

I am conducting analysis on drugs used to treat inflammatory diseases and kindly request your help.

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of May 2023 to the end of July 2023 (or the latest available 3 months).

I have provided a grid of drug names and disease names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

If data is unavailable for question 1 it would be helpful if you can provide the information at a department level (question 2).

Appendix A

Q1 – How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)						
Adalimumab (Biosimilars)						
Apremilast						
Bimekizumab						
Brodalumab						
Certolizumab Pegol						
Deucravacitinib						
Etanercept (Enbrel)						
Etanercept (Biosimilars)						
Guselkumab						
Infliximab (Remicade)						
Infliximab (Biosimilars)						
Ixekizumab						
Risankizumab						
Secukinumab						
Tildrakizumab						
Ustekinumab						
Upadacitinib						
Vedolizumab						
Filgotinib						
Golimumab						
Mirikizumab						
Ozanimod						
Tofacitinib						
Abatacept						
Baricitinib						
Rituximab						
Sarilumab						
Tocilizumab						

Q2 – How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)			
Adalimumab (Biosimilars)			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept (Enbrel)			
Etanercept (Biosimilars)			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			
Tofacitinib			
Abatacept			
Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Our response

We are not able to provide information on the treatment drugs prescribed to individual patients as it is not recorded centrally. To comply with your request, we would need to review every patient record which we have established would take in excess of 18 hours to undertake and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.